456 related articles for article (PubMed ID: 36588797)
1. A Cuproptosis-Related lncRNAs Signature Could Accurately Predict Prognosis in Patients with Clear Cell Renal Cell Carcinoma.
Zhang W; Wang H; Wang W; Xue H; Qiao M; Song L; Wang S; Ren Z; Ma Z
Anal Cell Pathol (Amst); 2022; 2022():4673514. PubMed ID: 36588797
[TBL] [Abstract][Full Text] [Related]
2. Establishment of a prognostic signature for lung adenocarcinoma using cuproptosis-related lncRNAs.
Yalimaimaiti S; Liang X; Zhao H; Dou H; Liu W; Yang Y; Ning L
BMC Bioinformatics; 2023 Mar; 24(1):81. PubMed ID: 36879187
[TBL] [Abstract][Full Text] [Related]
3. Development and validation of a novel 5 cuproptosis-related long noncoding RNA signature to predict diagnosis, prognosis, and drug therapy in clear cell renal cell carcinoma.
Chen Y; Hu W; Wei X; Zhang L; Shao Y; Tian J; Wang D; Wu B
Transl Androl Urol; 2023 Apr; 12(4):622-641. PubMed ID: 37181235
[TBL] [Abstract][Full Text] [Related]
4. Identification and Validation of Cuproptosis-Related LncRNA Signatures in the Prognosis and Immunotherapy of Clear Cell Renal Cell Carcinoma Using Machine Learning.
Bai Z; Lu J; Chen A; Zheng X; Wu M; Tan Z; Xie J
Biomolecules; 2022 Dec; 12(12):. PubMed ID: 36551318
[TBL] [Abstract][Full Text] [Related]
5. Cuproptosis-Related LncRNA-Based Prediction of the Prognosis and Immunotherapy Response in Papillary Renal Cell Carcinoma.
Pang Y; Wang Y; Zhou X; Ni Z; Chen W; Liu Y; Du W
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674979
[TBL] [Abstract][Full Text] [Related]
6. A cuproptosis-related long non-coding RNA signature to predict the prognosis and immune microenvironment characterization for lung adenocarcinoma.
Ma S; Zhu J; Wang M; Zhu J; Wang W; Xiong Y; Jiang R; Seetharamu N; Abrão FC; Puthamohan VM; Liu L; Jiang T
Transl Lung Cancer Res; 2022 Oct; 11(10):2079-2093. PubMed ID: 36386454
[TBL] [Abstract][Full Text] [Related]
7. A novel cuproptosis-related lncRNAs signature predicts prognosis in bladder cancer.
Wu L; Chen W; Cao Y; Chen B; He Y; Wang X
Aging (Albany NY); 2023 Jul; 15(13):6445-6466. PubMed ID: 37424068
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive analysis of cuproptosis-related lncRNAs for prognostic significance and immune microenvironment characterization in hepatocellular carcinoma.
Li D; Jin S; Chen P; Zhang Y; Li Y; Zhong C; Fan X; Lin H
Front Immunol; 2022; 13():991604. PubMed ID: 36685508
[TBL] [Abstract][Full Text] [Related]
9. Cuproptosis-related lncRNA signature for prognostic prediction in patients with acute myeloid leukemia.
Zhu Y; He J; Li Z; Yang W
BMC Bioinformatics; 2023 Feb; 24(1):37. PubMed ID: 36737692
[TBL] [Abstract][Full Text] [Related]
10. Prognostic and immune microenvironment analysis of cuproptosis-related LncRNAs in breast cancer.
Pan Y; Zhang Q; Zhang H; Kong F
Funct Integr Genomics; 2023 Jan; 23(1):38. PubMed ID: 36640225
[TBL] [Abstract][Full Text] [Related]
11. Computational construction of TME-related lncRNAs signature for predicting prognosis and immunotherapy response in clear cell renal cell carcinoma.
Zhou L; Fang H; Guo F; Yin M; Long H; Weng G
J Clin Lab Anal; 2022 Aug; 36(8):e24582. PubMed ID: 35808868
[TBL] [Abstract][Full Text] [Related]
12. A novel cuproptosis-related lncRNA signature predicts the prognosis and immunotherapy for hepatocellular carcinoma.
Liu Y; Jiang J
Cancer Biomark; 2023; 37(1):13-26. PubMed ID: 37005878
[TBL] [Abstract][Full Text] [Related]
13. A novel signature to guide osteosarcoma prognosis and immune microenvironment: Cuproptosis-related lncRNA.
Yang M; Zheng H; Xu K; Yuan Q; Aihaiti Y; Cai Y; Xu P
Front Immunol; 2022; 13():919231. PubMed ID: 35967366
[TBL] [Abstract][Full Text] [Related]
14. The LncRNA signature associated with cuproptosis as a novel biomarker of prognosis in immunotherapy and drug screening for clear cell renal cell carcinoma.
Zhang L; Di L; Liu J; Lei X; Gu M; Zhang W; Wang Y
Front Genet; 2023; 14():1039813. PubMed ID: 36755568
[TBL] [Abstract][Full Text] [Related]
15. Development of a novel disulfidptosis-related lncRNA signature for prognostic and immune response prediction in clear cell renal cell carcinoma.
Wang N; Hu Y; Wang S; Xu Q; Jiao X; Wang Y; Yan L; Cao H; Shao F
Sci Rep; 2024 Jan; 14(1):624. PubMed ID: 38182642
[TBL] [Abstract][Full Text] [Related]
16. Cuproptosis-related lncRNA scoring system to predict the clinical outcome and immune landscape in pancreatic adenocarcinoma.
Huang Y; Gong P; Su L; Zhang M
Sci Rep; 2023 Nov; 13(1):20870. PubMed ID: 38012210
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive analysis of cuproptosis-related lncRNAs in immune infiltration and prognosis in hepatocellular carcinoma.
Liu C; Wu S; Lai L; Liu J; Guo Z; Ye Z; Chen X
BMC Bioinformatics; 2023 Jan; 24(1):4. PubMed ID: 36597032
[TBL] [Abstract][Full Text] [Related]
18. Cuproptosis-related lncRNA signature as a prognostic tool and therapeutic target in diffuse large B cell lymphoma.
Bai X; Lu F; Li S; Zhao Z; Wang N; Zhao Y; Ma G; Zhang F; Su X; Wang D; Ye J; Li P; Ji C
Sci Rep; 2024 Jun; 14(1):12926. PubMed ID: 38839842
[TBL] [Abstract][Full Text] [Related]
19. Prognostic signature construction and immunotherapy response analysis for Uterine Corpus Endometrial Carcinoma based on cuproptosis-related lncRNAs.
Zhang X; Ye Z; Xiao G; He T
Comput Biol Med; 2023 Jun; 159():106905. PubMed ID: 37060773
[TBL] [Abstract][Full Text] [Related]
20. Machine learning-driven prognostic analysis of cuproptosis and disulfidptosis-related lncRNAs in clear cell renal cell carcinoma: a step towards precision oncology.
Chen R; Wu J; Che Y; Jiao Y; Sun H; Zhao Y; Chen P; Meng L; Zhao T
Eur J Med Res; 2024 Mar; 29(1):176. PubMed ID: 38491523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
